
Macrocure nets $49.8mm through IPO
Executive Summary
Israeli wound therapy developer Macrocure Ltd. completed its initial public offering in the US, netting $49.8mm through the sale of 5.35mm ordinary shares at $10 (below its intended range of $13-15).
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com